28-MAR-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3956 362 203 103 40 11 02/06/2019 472 182
Screened at PD     1459 204 133 73 33 9      
Pre-Screened prior to PD     2477 138 60 26 7 2      
Treatment-naive     20 20 10 4 0 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     529 29 16 9 3 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2133 375 157 78 33 6      
Screened at PD     1222 226 126 64 29 5      
Pre-Screened prior to PD     834 124 19 8 3 0      
Treatment-naive     20 20 10 5 0 0      
After PD on a Lung_MAP Sub-Study     57 5 2 1 1 1      
 
Sub-Study Assignments (open studies only)
S1800E     335 335 136 66 32 5      
S1900G     35 7 3 2 1 1      
S1900J     17 6 4 2 0 0      
S1900K     36 27 14 8 0 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     607 111 70 42 18 7      
Initial sub-study registrations     595 111 70 42 18 7      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 81 81 56 33 17 7 05/22/2025 350 111
Docetaxel plus Ramucirumab Y   42 42 29 17 9 4      
Cemiplimab plus Docetaxel and Ramucirumab Y   39 39 27 16 8 3      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 24 6 2 1 0 0 05/05/2023 342 109
Capmatinib + Osimertinib + Ramucirumab Y   14 5 2 1 0 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 4 3 2 1 1 0 11/19/2024 242 80
Amivantamab Hyaluronidase Y   4 3 2 1 1 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 24 21 10 7 0 0 08/08/2024 270 89
Tepotinib + Ramucirumab Y   16 14 7 6 0 0      
Tepotinib Y   8 7 3 1 0 0